Market Spotlight: Primary Sclerosing Cholangitis
|出版日期||內容資訊||英文 27 Pages
|焦點市場分析:原發性硬化性膽管炎 (PSC) Market Spotlight: Primary Sclerosing Cholangitis|
|出版日期: 2020年08月12日||內容資訊: 英文 27 Pages||
本報告提供全球原發性硬化性膽管炎 (PSC) 治療藥市場相關調查分析，提供主要的開發平台藥物，最近的趨勢和分析師的見解，臨床實驗，成功的概率，今後趨勢與法規趨勢，專利資訊，10年的發病率預測，許可證·收購交易，收益預測相關的系統性資訊。
Primary sclerosing cholangitis (PSC) is a progressive, rare, and chronic cholestatic liver disorder that is characterized by thickening, inflammation, and fibrosis of the bile ducts. Both intra- and extra-hepatic bile ducts are affected. This generally leads to cholestasis, liver cirrhosis, and eventually liver failure.
Datamonitor Healthcare estimates that in 2019, there were 241,800 prevalent cases of primary sclerosing cholangitis (PSC) worldwide among adults aged 30 years and over, and forecasts that number to increase to 277,300 prevalent cases by 2028. * * The majority of industry-sponsored drugs in active clinical development for PSC are in Phase II, with only two drugs in Phase III. Therapies in the pipeline for PSC focus on a wide variety of targets. The majority of pipeline drugs in development are administered via the oral route, with the remainder being tested in intravenous and subcutaneous formulations.
The only high-impact upcoming event for drugs in the PSC space is topline Phase II trial results for HTD1801. The overall likelihood of approval of a Phase I autoimmune/immunology-other asset is 21.8%, and the average probability a drug advances from Phase III is 70.2%. Drugs, on average, take 9.8 years from Phase I to approval, compared to 9.0 years in the overall autoimmune/immunology space.
The distribution of clinical trials across Phase I-IV indicates that the majority of trials for PSC have been in the early and midphases of development, with 80% of trials in Phase I-II, and only 20% in Phase III.
The US leads in terms of the number of PSC clinical trials globally, while the UK leads the major European markets.
Gilead Sciences has two completed trials and two ongoing trials in PSC.
Gilead Sciences has conducted two Phase II trials for PSC, as well as a single trial in Phase I and in Phase III.